CN112111012B - 共价多特异性抗体 - Google Patents
共价多特异性抗体 Download PDFInfo
- Publication number
- CN112111012B CN112111012B CN201910535703.7A CN201910535703A CN112111012B CN 112111012 B CN112111012 B CN 112111012B CN 201910535703 A CN201910535703 A CN 201910535703A CN 112111012 B CN112111012 B CN 112111012B
- Authority
- CN
- China
- Prior art keywords
- domain
- amino acid
- target
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001413 amino acids Chemical class 0.000 claims abstract description 87
- 238000006467 substitution reaction Methods 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims description 130
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 130
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 130
- 235000001014 amino acid Nutrition 0.000 claims description 54
- 235000018417 cysteine Nutrition 0.000 claims description 40
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 36
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 36
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 33
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 32
- 210000004899 c-terminal region Anatomy 0.000 claims description 25
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 18
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 18
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 9
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 9
- 150000001945 cysteines Chemical group 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 239000004471 Glycine Chemical group 0.000 claims 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 230000002147 killing effect Effects 0.000 abstract description 10
- 230000004614 tumor growth Effects 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000000710 homodimer Substances 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 70
- 125000003275 alpha amino acid group Chemical group 0.000 description 36
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 25
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 25
- 238000000034 method Methods 0.000 description 16
- 239000006143 cell culture medium Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000012636 effector Substances 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229960003008 blinatumomab Drugs 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000010276 construction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229940125644 antibody drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012492 Biacore method Methods 0.000 description 4
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 4
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 108010005636 polypeptide C Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940022836 benlysta Drugs 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
抗原 | ka(1/Ms) | kd(1/s) | KD(M) |
CD3 | 4.876E+5 | 0.01530 | 3.137E-8 |
CD19 | 3.653E+5 | 6.686E-4 | 1.830E-9 |
抗原 | ka(1/Ms) | kd(1/s) | KD(M) |
CD3 | 3.342E+5 | 0.008349 | 2.498E-8 |
CD19 | 2.068E+5 | 2.727E-4 | 1.319E-9 |
Claims (10)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910535703.7A CN112111012B (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
CN202310708851.0A CN116987197A (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
PCT/CN2020/087668 WO2020253393A1 (zh) | 2019-06-20 | 2020-04-29 | 共价多特异性抗体 |
JP2021576262A JP2022537823A (ja) | 2019-06-20 | 2020-04-29 | 共有結合型多重特異性抗体 |
US17/596,789 US20230192898A1 (en) | 2019-06-20 | 2020-04-29 | Covalent multi-specific antibody |
EP20826093.5A EP3988575A4 (en) | 2019-06-20 | 2020-04-29 | COVALENT MULTI-SPECIFIC ANTIBODY |
US18/668,012 US12134661B1 (en) | 2019-06-20 | 2024-05-17 | Covalent multi-specific antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910535703.7A CN112111012B (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310708851.0A Division CN116987197A (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112111012A CN112111012A (zh) | 2020-12-22 |
CN112111012B true CN112111012B (zh) | 2023-07-04 |
Family
ID=73795815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910535703.7A Active CN112111012B (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
CN202310708851.0A Pending CN116987197A (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310708851.0A Pending CN116987197A (zh) | 2019-06-20 | 2019-06-20 | 共价多特异性抗体 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20230192898A1 (zh) |
EP (1) | EP3988575A4 (zh) |
JP (1) | JP2022537823A (zh) |
CN (2) | CN112111012B (zh) |
WO (1) | WO2020253393A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SMT202500043T1 (it) | 2014-12-15 | 2025-03-12 | Univ California | Recettore antigenico chimerico bispecifico or-gate sensibile a cd19 e cd20 |
WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング,インコーポレイテッド | ガレクチン-3を遮断することにより炎症性疾患を処置する方法 |
AU2023319874A1 (en) * | 2022-08-05 | 2025-02-27 | Chimagen Biosciences, Ltd | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014047231A1 (en) * | 2012-09-21 | 2014-03-27 | Regeneron Pharmaceuticals, Inc. | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
TW201439117A (zh) * | 2013-03-15 | 2014-10-16 | Amgen Inc | 異二聚雙特異性抗體 |
CN107484416A (zh) * | 2014-09-26 | 2017-12-15 | 宏观基因有限公司 | 能够结合cd19和cd3的双特异性单价双抗体及其用途 |
CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
CN109476732A (zh) * | 2016-04-13 | 2019-03-15 | 赛诺菲 | 三特异性和/或三价结合蛋白 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
KR20220082104A (ko) * | 2010-11-30 | 2022-06-16 | 추가이 세이야쿠 가부시키가이샤 | 세포상해 유도 치료제 |
ES2659764T3 (es) * | 2011-08-23 | 2018-03-19 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T |
MX2016006301A (es) * | 2013-11-13 | 2016-12-16 | Zymeworks Inc | Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos. |
HRP20200164T1 (hr) * | 2014-03-28 | 2020-05-01 | Xencor, Inc. | Bispecifična protutijela koja se vežu na cd38 i cd3 |
MA40069A (fr) * | 2014-05-29 | 2021-04-14 | Macrogenics Inc | Molécules de liaison trispécifiques et leurs procédés d'utilisation |
JP6937746B2 (ja) * | 2015-10-02 | 2021-09-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗cd19×cd3t細胞活性化抗原結合分子 |
CR20180149A (es) * | 2015-10-02 | 2018-04-05 | Hoffmann La Roche | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso |
US11685776B2 (en) * | 2017-03-02 | 2023-06-27 | Novartis Ag | Engineered heterodimeric proteins |
CN109706163A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用 |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
US11780926B2 (en) * | 2018-03-22 | 2023-10-10 | Universität Stuttgart | Multivalent binding molecules |
-
2019
- 2019-06-20 CN CN201910535703.7A patent/CN112111012B/zh active Active
- 2019-06-20 CN CN202310708851.0A patent/CN116987197A/zh active Pending
-
2020
- 2020-04-29 WO PCT/CN2020/087668 patent/WO2020253393A1/zh unknown
- 2020-04-29 US US17/596,789 patent/US20230192898A1/en active Pending
- 2020-04-29 EP EP20826093.5A patent/EP3988575A4/en active Pending
- 2020-04-29 JP JP2021576262A patent/JP2022537823A/ja active Pending
-
2024
- 2024-05-17 US US18/668,012 patent/US12134661B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014047231A1 (en) * | 2012-09-21 | 2014-03-27 | Regeneron Pharmaceuticals, Inc. | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
TW201439117A (zh) * | 2013-03-15 | 2014-10-16 | Amgen Inc | 異二聚雙特異性抗體 |
CN107484416A (zh) * | 2014-09-26 | 2017-12-15 | 宏观基因有限公司 | 能够结合cd19和cd3的双特异性单价双抗体及其用途 |
CN109476732A (zh) * | 2016-04-13 | 2019-03-15 | 赛诺菲 | 三特异性和/或三价结合蛋白 |
CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
Non-Patent Citations (1)
Title |
---|
双功能抗体抗CD3/抗CD19介导T细胞对靶细胞的杀伤作用;范冬梅等;《中国癌症杂志》;20110120;第21卷(第01期);第6-11页 * |
Also Published As
Publication number | Publication date |
---|---|
EP3988575A4 (en) | 2023-08-16 |
EP3988575A1 (en) | 2022-04-27 |
CN116987197A (zh) | 2023-11-03 |
US20230192898A1 (en) | 2023-06-22 |
CN112111012A (zh) | 2020-12-22 |
JP2022537823A (ja) | 2022-08-30 |
US20240352155A1 (en) | 2024-10-24 |
US12134661B1 (en) | 2024-11-05 |
WO2020253393A1 (zh) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112111012B (zh) | 共价多特异性抗体 | |
JP2018531219A (ja) | Pd−l1抗体 | |
JP2018531219A6 (ja) | Pd−l1抗体 | |
CN106831996B (zh) | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 | |
CN110799546B (zh) | 重组双特异性抗体 | |
CN105722855A (zh) | 恒定链经修饰的双特异性五价和六价Ig-M抗体 | |
WO2018176992A1 (zh) | 新型双特异性抗体及其用途 | |
KR102291725B1 (ko) | 항-cntn4 항체 및 그의 용도 | |
US20230071422A1 (en) | ANTI-CD3 and ANTI-CD123 Bispecific Antibody and Use Thereof | |
CN111655733A (zh) | 共价多特异性抗体 | |
JP2023182689A (ja) | 抗cldn4-抗cd137二重特異性抗体 | |
WO2023273595A1 (zh) | 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用 | |
CN118290582A (zh) | 抗人Claudin18.2抗体及其应用 | |
TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
WO2021047386A1 (zh) | 靶向caix抗原的纳米抗体及其应用 | |
CN112961250A (zh) | 抗体融合蛋白及其应用 | |
CN110872356B (zh) | 双特异性抗体及其使用方法 | |
WO2022267702A1 (zh) | 结合bcma和cd3的双特异性抗体及其制备方法与应用 | |
CN116554340A (zh) | 新型长效化和高活性且更安全的抗体构建体 | |
WO2022111706A1 (en) | Novel anti-lag3 antibodies and methods of making and using the same | |
CN114573704B (zh) | Pd-1/ctla-4结合蛋白及其医药用途 | |
WO2023187460A1 (en) | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function | |
TW202333788A (zh) | 一種抗tnfr2抗體藥物組合物 | |
CN118159559A (zh) | 一种抗b7-h4抗体及其制备方法和应用 | |
CN117304331A (zh) | 一种抗pd-1和pcsk9的双特异性抗体及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221220 Address after: No.1, 9 / F, building 1, No.5, Keyuan South Road, Chengdu hi tech Zone, Chengdu, Sichuan 610041 Applicant after: CHIMAGEN BIOSCIENCES, Ltd. Applicant after: Zhejiang Borui biopharmaceutical Co.,Ltd. Address before: No.1, 9 / F, building 1, No.5, Keyuan South Road, Chengdu hi tech Zone, Chengdu, Sichuan 610041 Applicant before: CHIMAGEN BIOSCIENCES, Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240914 Address after: No.1, 9 / F, building 1, No.5, Keyuan South Road, Chengdu hi tech Zone, Chengdu, Sichuan 610041 Patentee after: CHIMAGEN BIOSCIENCES, Ltd. Country or region after: China Address before: No.1, 9 / F, building 1, No.5, Keyuan South Road, Chengdu hi tech Zone, Chengdu, Sichuan 610041 Patentee before: CHIMAGEN BIOSCIENCES, Ltd. Country or region before: China Patentee before: Zhejiang Borui biopharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20241206 Address after: Cayman Islands Grand Cayman Island Kamana Bay Patentee after: Cayman Kaijin Biotechnology Country or region after: Cayman Islands Address before: No.1, 9 / F, building 1, No.5, Keyuan South Road, Chengdu hi tech Zone, Chengdu, Sichuan 610041 Patentee before: CHIMAGEN BIOSCIENCES, Ltd. Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20241213 Address after: Cayman Islands Grand Cayman Island West Bay Road Patentee after: XNext Bioscience Co. Country or region after: Cayman Islands Address before: Cayman Islands Grand Cayman Island Kamana Bay Patentee before: Cayman Kaijin Biotechnology Country or region before: Cayman Islands |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20250117 Address after: Steve Niki Patentee after: GlaxoSmithKlay Intellectual Property (No.3) Co.,Ltd. Country or region after: Britain Address before: Cayman Islands Grand Cayman Island West Bay Road Patentee before: XNext Bioscience Co. Country or region before: Cayman Islands |